Perspective
Our work in Perspective
-
What the Trump Administration Gets Right About Hospital Price Transparency
Would you buy a pair of shoes without knowing the price? Consumers have bought medical care from hospitals for years without knowing the costs, but new regulations will change that.
Categorized in -
To Really Cut Health Spending, Put Pharmacists on the Front Line
Sixteen percent of all U.S. healthcare expenditures can be attributed to patients failing to properly adhere to their prescriptions. Pharmacists can be an important, and valuable, part of a patient’s care team.
Categorized in -
Who Pays in Medicare Part D? Giving Plans More Skin in the Game
Private plans have the potential to lead the way toward innovative contracting approaches that emphasize value and, in doing so, deliver on the original vision for the Part D marketplace.
Categorized in -
PODCAST: The Biggest Health Care Issues of the 2020 Election
In this episode of the Brookings Cafeteria podcast, health policy experts from the USC-Brookings Schaeffer Initiative discuss the presidential candidates’ health proposals, and also look at what to do about surprise medical billing.
-
The Success of Medicare Advantage Makes it a Better Policy Choice than ‘Medicare for All’
This public-private partnership is delivering high-quality health care at comparatively low cost.
Categorized in -
Older People Have Smaller But Closer Social Networks
Are older people really more lonely? This study finds that older adults have fewer social contacts, although the number of close friends tends to be relatively stable across adults of all ages. It is the number of close friends, and how we feel about them, that seems to benefit our well-being.
Categorized in -
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
Categorized in -
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Categorized in -
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
Categorized in -
Retroactive Enrollment: A Feasible Way to Bring Auto-Enrollment to the Individual Market
Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.
Categorized in